

Title:

Validation of a rapid test for celiac disease detection in first-degree relatives - A prospective study

Authors:

Maria Pascual Lorén, Ana Martín Adrados, Rosa María González Cervera, Jorge Martínez Pérez, Ana Isabel Quintero García, Rosa Ana Muñoz Codoceo

DOI: 10.17235/reed.2024.10791/2024

Link: [PubMed \(Epub ahead of print\)](#)

Please cite this article as:

Pascual Lorén María, Martín Adrados Ana, González Cervera Rosa María , Martínez Pérez Jorge , Quintero García Ana Isabel , Muñoz Codoceo Rosa Ana. Validation of a rapid test for celiac disease detection in first-degree relatives - A prospective study. Rev Esp Enferm Dig 2024. doi: 10.17235/reed.2024.10791/2024.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Validation of a rapid test for celiac disease detection in first-degree relatives - A prospective study

Pascual Loren, María¹; Martín-Adrados Ana²; González Cervera, Rosa María¹; Martínez Pérez, Jorge³; Quintero García, Ana Isabel¹; Muñoz Codoceo, Rosa Ana³

¹Department of Clinical Analysis. Hospital Infantil Universitario Niño Jesús. Madrid.

²Hospital Infantil Universitario Niño Jesús. ³Department of Gastroenterology. Hospital Infantil Universitario Niño Jesús. Madrid

mariapascualloren@hotmail.es

Keywords: Celiac disease. Rapid test.

Dear Editor,

Celiac disease (CD) is an autoimmune condition triggered by gluten in genetically susceptible individuals. Based on the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) 2020 guidelines, the primary diagnosis of CD relies on the detection of anti-Tissue Transglutaminase type 2 antibodies (anti-tTG2) in serum. (1)

As it is an HLA-dependent condition, first-degree relatives (FDRs) of celiac patients are at higher risk than general population of developing CD. A meta-analysis which compared 54 articles showed that the pooled prevalence of CD was 7.5% among FDRs and 2.3% among second-degree relatives compared to 1.4% in the general population (2). They may be asymptomatic or present very mild symptoms, manifesting in silent, latent, or potential forms of the disease. Despite the absence of symptoms, diagnosis is essential to start a gluten-free diet and prevent complications associated with nutrient malabsorption and immune system dysfunction.

The study we present aims to validate CeliacDetect (Biomedal S.L., Seville, Spain), a new rapid diagnosis test for CD. It is a Lateral Flow Immunoassay (LFIA) for outpatient use, which allows detecting the presence of anti-tTG2 IgA antibodies in capillary blood samples obtaining a result in 10 minutes. This test can be performed in the daily practice at the medical clinic as it is easy and minimally invasive. First step is to clean and massage with an alcohol pad the fingertip and then puncture it using an automatic lancet. A blood drop is collected in the glass capillary tube. Once the tube, approximately 2 cm in length, is filled, it is placed into a buffer bottle and mixed by inverting. Finally, five drops of this mixture are applied to the LFIA.

A qualitative result is given. If the sample contains anti-tTG2 antibodies, a red line appears (positive result), which indicates the possibility of suffering from CD considering anti-tTG2 > 5 U/mL as positive. The absence of this line (negative result), confirms that the blood sample does not contain anti-tTG2 antibodies within the detection limits of the kit and, therefore, a low suspicion of CD.

A prospective, single-center study was coordinated between the Clinical Analysis Laboratory and the Gastroenterology Department from March 2023 to March 2024. Informed consent was obtained from all patients over 12 years old and parents or legal guardians of subjects involved in the study which were under 12. First-degree relatives of CD patients were tested in situ, making the CeliacDetect rapid test and comparing it with the routine laboratory technique (serum anti-tTG2 determination along with total IgA levels).

For this purpose, the IDS t-TG IgA diagnostic kit was used, a chemiluminescence immunoassay (CLIA) for the quantitative determination of IgA-specific antibodies directed against tissue anti-transglutaminase (t-TG) in human serum or plasma samples. A sample is considered positive if it presents titers higher than 10 IU/ml. This posed a limitation because there is a gray area between the positive result of the Celiacdetect test (>5 IU/mL) and the positive result of the laboratory technique. Previously diagnosed CD cases or those with IgA deficiency were excluded.

The study included 95 participants, FDRs of CD patients consisting of 27 (28%) mothers, 27 (28%) fathers, and 41 (43%) siblings of diagnosed CD patients. Five potential participants were excluded, two because they did not undergo the laboratory sample extraction, and three with IgA deficiency. Eight patients (8.8%) tested positive in the rapid test and all of them (100%) were subsequently confirmed to have CD with values of anti-tTG2 > 100 U/mL by the routine laboratory technique. All were siblings of CD patients, aged between 2 and 15 years. The remaining patients (91%) were negative for both determinations (Table 1).

This appears to be a very positive result in terms of accuracy, as both sensitivity and specificity were 100%, as well as the positive and negative predictive values. In addition to evaluating the sensitivity and specificity of the test, a ROC curve (Figure 1) analysis was also performed to assess its discriminative ability. The ROC curve showed an area under the curve (AUC) of 1, indicating a high level of accuracy in the test's ability to distinguish between patients with CD and those without it.

In this same line of CD research, there have been few other publications that advocate for the use of this rapid tests for screening (3, 4), simple and quick to use in a usual medical consultation. When comparing the results obtained, the test used in this study is one of the most accurate (PPV 100%), which would translate to a reduction in the number of people sent for additional laboratory tests resulting in a decrease in costs, risks, and refusals of diagnosis.

These results further support the utility of the rapid test as an effective tool for screening CD in relatives of diagnosed patients. However, it would be important to perform more studies with wider sample size. As IgA antibodies are detected, having an IgA deficiency is an evident limitation to use this test.

As recommended in the latest clinical practice guidelines, screening based on genetic risk should be done (5). We propose that at the time of diagnosing a celiac patient, a blood test with HLA determination should be performed to his/her siblings, to assess

the risk and in that same sample measure total IgA. Based on the risk according to the HLA, monitoring can be done, with the following determinations being carried out with the rapid Celiacdetect test once IgA deficiency has been ruled out.

This study brings the novelty of using a quick and easy test for screening. This finding could have a significant impact on clinical practice by enabling early and accessible detection of the disease in first-degree relatives, which may lead to timely intervention and improved quality of life for patients.

REFERENCES


1. Husby S, Koletzko S, Korponay-Szabó I, et al. European society paediatric gastroenterology, hepatology and nutrition guidelines for diagnosing coeliac disease 2020. *Journal of Pediatric Gastroenterology and Nutrition* 2020; 70.1:141-156. DOI obtained: 10.1097/MPG.0000000000002497
2. Prashant S, Shubhangi A, Suman L, et al. Risk of Celiac Disease in the First- and Second-Degree Relatives of Patients With Celiac Disease: A Systematic Review and Meta-Analysis. *American Journal of Gastroenterology*. November 2015. 110(11): p 1539-1548. DOI obtained: 10.1038/ajg.2015.296
3. Mendia I, Segura V, Ruiz-Carnicer Á, et al. Rapid Anti-tTG-IgA Screening Test for Early Diagnosis of Celiac Disease in Pediatric Populations. *Nutrients*. November 2023. 26;15(23):4926. DOI obtained: 10.3390/nu15234926
4. Singh P, Wadhwa N, Chaturvedi MK, et al. Validation of point-of-care testing for celiac disease in children in a tertiary hospital in north India. *Archives of Disease in Childhood* 2014 ;99: 1004-1008. DOI obtained: 10.1136/archdischild-2013-305567
5. Donat E, Roca M, Torres R, Ribes-Koninckx C. Protocolo de despistaje de ENFERMEDAD CELÍACA en población pediátrica con familiar en primer grado afecto Documento de expertos de la SEGHNP. Julio 2020

Table 1

		Reference test		
		Positive	Negative	Total
Rapid test (CeliacDetect)	Positive	8	0	8
	Negative	0	82	82
	Total	8	82	90

Results of the rapid test CeliacDetect compared to the results obtained with the laboratory reference test.

Figure 1





Accepted Article